Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

Diabetes, Obesity & Metabolism
G SchernthanerElise Hardy

Abstract

To assess the efficacy and safety of adjunctive saxagliptin vs glimepiride in elderly patients with type 2 diabetes (T2D) and inadequate glycaemic control. In this multinational, randomized, double-blind, phase IIIb/IV study (GENERATION; NCT01006603), patients aged ≥65 years were randomized (1 : 1) to receive saxagliptin 5 mg/day or glimepiride ≤6 mg/day, added to metformin, during a 52-week treatment period. The primary endpoint was achievement of glycated haemoglobin (HbA1c) <7.0% at week 52 without confirmed/severe hypoglycaemia. The key secondary endpoint was incidence of confirmed/severe hypoglycaemia. Safety and tolerability were also assessed. Of 720 patients randomized (360 in each treatment group; mean age 72.6 years; mean T2D duration 7.6 years), 574 (79.8%) completed the study (saxagliptin 80.3%; glimepiride 79.2%). Similar proportions of patients achieved the primary endpoint with saxagliptin and glimepiride (37.9 vs 38.2%; odds ratio 0.99, 95% confidence interval 0.73, 1.34; p = 0.9415); however, a significant treatment-by-age interaction effect was detected (p = 0.0389): saxagliptin was numerically (but not significantly) superior to glimepiride for patients aged <75 years (39.2 vs 33.3%) and numerically inferior ...Continue Reading

References

Oct 19, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·V McAulayB M Frier
Aug 13, 2004·European Journal of Clinical Investigation·G SchernthanerK M Shaw
Apr 28, 2005·Diabetes Care·UNKNOWN Workgroup on Hypoglycemia, American Diabetes Association
Jan 18, 2006·Diabetes & Metabolism·P Lecomte
Jan 14, 2011·Diabetes Care·UNKNOWN American Diabetes Association
Feb 18, 2011·Current Medical Research and Opinion·Jean DoucetJulio Rosenstock
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
May 13, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Priscilla L HollanderUNKNOWN CV181013 Investigators
May 13, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Antonio R ChacraUNKNOWN CV181040 Investigators
Apr 26, 2013·BMJ : British Medical Journal·Laura A McLarenGerard A McKay
Aug 1, 2013·BMJ : British Medical Journal·Atsushi GotoMitsuhiko Noda
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Apr 19, 2019·The Cochrane Database of Systematic Reviews·Kasper S MadsenBianca Hemmingsen
Sep 30, 2020·Expert Opinion on Pharmacotherapy·Kazuki Orime, Yasuo Terauchi
Nov 20, 2015·Der Urologe. Ausg. A·G Glaeske
Feb 16, 2016·Expert Opinion on Drug Metabolism & Toxicology·Rose AndersonJeffrey W Stephens
Mar 1, 2016·Expert Opinion on Drug Safety·Simona CerneaItamar Raz
Nov 5, 2016·Diabetes/metabolism Research and Reviews·Tiansheng WangSharon Giovenale
Sep 30, 2015·Diabetes/metabolism Research and Reviews·Wenjia YangLinong Ji
Feb 9, 2018·Diabetologia·Guntram Schernthaner, Marie Helene Schernthaner-Reiter
Feb 14, 2019·Revista da Associação Médica Brasileira·Juan-Juan LiZhe-Shu Zheng
Nov 26, 2015·Diabetes, Obesity & Metabolism·C F Deacon, H E Lebovitz
Oct 7, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Mar 25, 2018·Diabetes/metabolism Research and Reviews·Jetty A OverbeekGiel Nijpels
May 1, 2016·Expert Review of Endocrinology & Metabolism·Marie Helene Schernthaner-Reiter, Guntram Schernthaner
Sep 26, 2015·Drugs·Sohita Dhillon
Apr 23, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Mikaela SjöstrandBoaz Hirshberg
Apr 15, 2016·Science Translational Medicine·Hui WangHongting Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.